Loss-of-function pathogenic variants in BRCA1 confer a predisposition to breast and ovarian
cancer. Genetic testing for sequence changes in BRCA1 frequently reveals a missense …

The BARD1 protein, which heterodimerizes with BRCA1, is encoded by a known breast
cancer susceptibility gene. While several BARD1 variants have been identified as pathogenic, …

Pathogenic variants in BRCA1 are associated with a greatly increased risk of hereditary
breast and ovarian cancer (HBOC). With the increased availability and affordability of genetic …

Delineating functionally normal variants from functionally abnormal variants in tumor suppressor
proteins is critical for cancer surveillance, prognosis, and treatment options. BRCA1 is a …

PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance
limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel …

Single nucleotide variants are the most frequent type of sequence changes detected in the
genome and these are frequently variants of uncertain significance (VUS). VUS are changes …

Loss-of-function mutations in BRCA1 confer a predisposition to breast and ovarian cancer.
Genetic testing for mutations in the BRCA1 gene frequently reveals a missense variant for …

Individuals with deleterious germline mutations in the tumor suppressor gene BRCA1 are at
an increased risk for breast and ovarian cancers that are associated with poor disease …

BRCA1 and BARD1 encode proteins that form a heterodimer critical for mediating tumor
suppression. Individuals with deleterious germline mutations in BRCA1 and BARD1 are at an …

A library of 3000 putative kinase inhibitors from the ChemBridge Corporation was first
screened by bioluminescence assay against Mycobacterium smegmatis, a non-virulent model …